- Home
- ACAD vs SWTX Comparison
ACAD vs SWTX Comparison
Compare ACAD & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SWTX
- Stock Information
- Founded
- ACAD 1993
- SWTX 2017
- Country
- ACAD United States
- SWTX United States
- Employees
- ACAD N/A
- SWTX N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACAD Health Care
- SWTX Health Care
- Exchange
- ACAD Nasdaq
- SWTX Nasdaq
- Market Cap
- ACAD 2.8B
- SWTX 3.0B
- IPO Year
- ACAD 2004
- SWTX 2019
- Fundamental
- Price
- ACAD $16.61
- SWTX $44.13
- Analyst Decision
- ACAD Buy
- SWTX Strong Buy
- Analyst Count
- ACAD 17
- SWTX 5
- Target Price
- ACAD $24.00
- SWTX $72.40
- AVG Volume (30 Days)
- ACAD 1.5M
- SWTX 1.9M
- Earning Date
- ACAD 05-07-2025
- SWTX 05-01-2025
- Dividend Yield
- ACAD N/A
- SWTX N/A
- EPS Growth
- ACAD N/A
- SWTX N/A
- EPS
- ACAD 1.36
- SWTX N/A
- Revenue
- ACAD $957,797,000.00
- SWTX $191,589,000.00
- Revenue This Year
- ACAD $13.07
- SWTX $85.98
- Revenue Next Year
- ACAD $9.97
- SWTX $69.16
- P/E Ratio
- ACAD $12.28
- SWTX N/A
- Revenue Growth
- ACAD 31.85
- SWTX 3417.33
- 52 Week Low
- ACAD $14.15
- SWTX $28.21
- 52 Week High
- ACAD $20.68
- SWTX $62.00
- Technical
- Relative Strength Index (RSI)
- ACAD 36.91
- SWTX 37.32
- Support Level
- ACAD $16.86
- SWTX $45.88
- Resistance Level
- ACAD $17.31
- SWTX $51.43
- Average True Range (ATR)
- ACAD 0.51
- SWTX 1.98
- MACD
- ACAD -0.00
- SWTX -0.79
- Stochastic Oscillator
- ACAD 23.24
- SWTX 4.28
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.